Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Partnership versus Sale

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Aug 02, 2023 11:05am

207 Views

Post# 35568970

RE:Partnership versus Sale

Journey clearly does not know what they are talking about.

Coffee has no royalty any longer as far as I know.

He has 1.8 million options plus some shares which I cannot look up right now. At any price above $2.5 bil forthe company he is set for life.

ONCY did not design the mBC trial. The investigators did. It is veyr hard to get an Ethics board to agree to not let people leave a trial if they are getting sicker. Remember they are very ill already.

Finally Coiffee does not decide what value at which ONCY would be sold or partnered. The board does on which he has a vote.
Stop implying you know these things.

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders